United States 119th Congress Status: In Committee Bipartisan · 20 D · 4 R cosponsors

HR 5605 — Medical Device Nonvisual Accessibility Act of 2025

Last action — Referred to the House Committee on Energy and Commerce.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the House. Introduced September 26, 2025. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the House.

Prognosis

Advancing 42% · moderate confidence

Where this bill stands today.

Odds of enactment

Low

How often bills like it became law.

  • In Committee

    Current position in the legislative process.

  • 24 sponsors

    1 primary, 23 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (20 D · 4 R) — cross-party backing.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

In plain language

The bill aims to address matters related to energy and commerce.

This legislation has been introduced to the House and is focused on energy and commerce topics. It is currently under consideration by the House Committee on Energy and Commerce.

Bill Text

Sections of law this bill changes

1 section in 1 law

From the bill's own amending language, matched to the official United States Code (current through Public Law 119-124).

Federal food, drug, and cosmetic act · 21 U.S.C. ch. 9 1 section
  • § 351 Adulterated drugs and devices Amends

    21 U.S.C. § 351

    The law today

    A drug or device shall be deemed to be adulterated— (a) Poisonous, insanitary, etc., ingredients; adequate controls in manufacture (1) If it consists in whole or in part of any filthy, putrid, or decomposed substance; or (2)(A) if it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health; or (B) if it is a drug and the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with current good manufacturing practice to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess; or (C) if it is a compounded positron emission tomography drug and the methods used in, or the facilities and controls used for, its compounding, processing, packing, or holding do not conform to or are not operated or administered in conformity with the positron emission tomography compounding standards and the official monographs of the United States Pharmacopoeia to assure that such drug meets the requirements of this chapter as to safety and has the identity and strength, and meets the quality and purity characteristics, that it purports or is represented to possess; or (3) if its container is composed, in whole or in part, of any poisonous or deleterious substance which may render the contents injurious to health; or (4) if (A) it bears or contains, for purposes of coloring only, a color additive which is unsafe within the meaning of section 379e(a) of this title, or (B) it is a color additive the intended use of which in or on drugs or devices is for purposes of coloring only and is unsafe within the meaning of section 379e(a) of this title; or (5) if it is a new animal drug which is unsafe within the meaning of section 360b of this title; or (6) if it is an animal feed bearing or containing a new animal drug, and such animal feed is unsafe within the meaning of section 360b of this title. (b) Strength, quality, or purity differing from official compendium If it purports to be or is represented as a drug the name of which is recognized in an official compendium, and its strength differs from, or its quality or purity falls below, the standard set forth in such compendium. Such determination as to strength, quality, or purity shall be made in accordance with the tests or methods of assay set forth in such compendium, except that whenever tests or methods of assay have not been prescribed in such compendium, or such tests or methods of assay as are prescribed are, in the judgment of the Secretary, insufficient for the making of such determination, the Secretary shall bring such fact to the attention of the appropriate body charged with the revision of such compendium, and if such body fails within a reasonable time to prescribe tests or methods of assay which, in the judgment of the Secretary, are sufficient for purposes of this paragraph, then the Secretary shall promulgate regulations prescribing appropriate tests or methods of assay in accordance with which such determination as to strength, quality, or purity shall be made. No drug defined in an official compendium shall be deemed to be adulterated under this paragraph because it differs from the standard of strength, quality, or purity therefor set forth in such compendium, if its difference in strength, quality, or purity from such standard is plainly stated on its label. Whenever a drug is recognized in both the United States Pharmacopoeia and the Homoeopathic Pharmacopoeia of the United States it shall be subject to the requirements of the United States Pharmacopoeia unless it is labeled and offered for sale as a homoeopathic drug, in which case it shall be subject to the provisions of the Homoeopathic Pharmacopoeia o...

    95 other bills also change this section · Follow it → Official text at uscode.house.gov ↗

How this bill changes current law

1 change Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill establishes nonvisual accessibility standards for certain medical devices and adds a new adulteration criterion for devices that do not meet these standards.

  • 21 U.S.C. 351

    Beginning on the effective date specified in subsection (e) of section 515D, if it is a covered device (as defined in such section), unless the device meets the nonvisual accessibility standard specified under such section or the Secretary issues a waiver with respect to the device under such section.

    This adds a new adulteration provision that requires covered devices to meet nonvisual accessibility standards.

Action History

  1. Introduced in House

  2. Introduced in House

  3. Referred to the House Committee on Energy and Commerce.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 23 co-sponsors · 523 not signed on

Sponsors (1)

Co-sponsors (23)

Not signed on (523)

523 members have not signed on to this bill.

Show all 523 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HR 5605?
HR 5605 is sponsored by Schakowsky, Janice D. (Democratic), Bacon, Don (Republican), Bishop, Sanford D. (Democratic), Casten, Sean (Democratic), Fitzpatrick, Brian K. (Republican), García, Jesús G. "Chuy" (Democratic), Norton, Eleanor Holmes (Democratic), Panetta, Jimmy (Democratic), Pocan, Mark (Democratic), Quigley, Mike (Democratic), Rutherford, John H. (Republican), Sessions, Pete (Republican), Smith, Adam (Democratic), Hayes, Jahana (Democratic), Craig, Angie (Democratic), Lynch, Stephen F. (Democratic), Ross, Deborah K. (Democratic), Walkinshaw, James R. (Democratic), Doggett, Lloyd (Democratic), McClellan, Jennifer L. (Democratic), Frost, Maxwell (Democratic), Raskin, Jamie (Democratic), McBath, Lucy (Democratic), and Latimer, George (Democratic).
What is the current status of HR 5605?
This bill is in committee in the House. Introduced September 26, 2025. It must pass committee before a floor vote.
Where can I track HR 5605?
Track HR 5605 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 5605

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HR 5605

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →